A Phase 4 interventional study of Boostrix™ and Saline placebo in Diphtheria-Tetanus-acellular Pertussis Vaccines, sponsored by GlaxoSmithKline. Completed at 35 sites in 6 countries. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-28.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing boostrix in Diphtheria — 3 open to participants now, 3 under way, none of them phase 3. Boostrix · Diphtheria.
Among the 21 studies testing boostrix in Diphtheria, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 9 in phase 4, and was the 17th registered.
267 studies on the registry are indexed under Diphtheria; 17 are open to participants now.
Browse Diphtheria studies →3 of the 21 studies testing boostrix in Diphtheria are open now, in 2 countries. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Canadian Immunization Research Network · Sites in Canada
Ages 18–49 · Women only
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2015.
This study's enrollment of 688 is above the median of 448 across 241 interventional studies indexed under Diphtheria.
Median enrollment 460 across the 21 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
101 studies in Diphtheria by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 99 finished, 59 (60%) have results posted.
Among the 101 studies in Diphtheria by GlaxoSmithKline, this one is the 24th largest by enrollment of the 92 interventional ones that give a count, is one of 3 that started in 2015, is one of 22 in phase 4, and was the 88th registered.
GlaxoSmithKline’s Diphtheria studies by the year they started, since 1997.
1 of the studies testing boostrix in Diphtheria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07097012Canadian Immunization Research NetworkConcurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing boostrix in Diphtheria, from their registry updates:
Among GlaxoSmithKline’s 101 in Diphtheria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45 years. Infants born to mothers enrolled in this study will be followed-up in two separate clinical studies: 201330 [DTPA (BOOSTRIX)-048 PRI] and 201334 [DTPA (BOOSTRIX)-049 BST: 048].
The protocol was amended to include Spain in the study. The reasons for the Spain-specific amendment are listed below:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria for household contacts in Spain:
Female household contacts of non- may be enrolled in the study.
- Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
Female household contacts of childbearing potential may be enrolled in the study , if the household contact
Exclusion Criteria for study subjects:
Acute disease and/or fever at the time of enrolment.
Exclusion criteria for household contacts in Spain:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
Biological: Boostrix™ · Drug: Saline placebo
This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
Biological: Boostrix™ · Drug: Saline placebo
One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Antibody Concentrations Against Pertussis Toxoid Antigen (Anti-PT), Filamentous Haemagglutinin Antigen (Anti-FHA) and Pertactin Antigen (Anti-PRN) in Cord Blood Samples
Antibody concentrations were assessed by Enzyme-linked immunosorbent assay (ELISA), tabulated as Geometric Mean Concentrations (GMCs) and expressed in International units per mililiter (IU/mL) for the following assay cut-offs: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.
Time frame: At delivery - Visit 3 (anytime after 28 weeks of gestation)
Percentage of Subjects by Pregnancy Outcomes
Pregnancy outcomes included live birth with no congenital anomalies, live birth with congenital anomalies, still birth with no congenital anomalies, still birth with congenital anomalies, elective termination with no congenital anomalies and elective termination with congenital anomalies. No subjects with still birth or elective termination of infant were reported.
Time frame: From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).
Percentage of Subjects With Listed Pregnancy/Neonate Related Adverse Events of Interest
Listed pregnancy-related adverse events of interest/ neonate-related events of interest included gestational diabetes, pregnancy-related hypertension, premature rupture of mem-branes, preterm premature rupture of membranes, premature labour, premature uterine contractions, intrauterine growth restriction/poor foetal growth, pre-eclampsia, eclampsia, vaginal or intrauterine haemorrhage, maternal death, preterm birth, neonatal death, small for gestational age, neonatal hypoxic ischaemic encephalopathy and failure to thrive/growth deficiency were reported.
Time frame: From Day 0 (Visit 1) to Month 2 post-delivery (Visit 4, end of the study).
Percentage of Seroprotected Subjects Against Diphteria Antigen (Anti-D), Tetanus Antigen (Anti-T) and of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN
A seroprotected subject against diphteria and tetanus was a subject with antibody concentration ≥ 0.1 IU/mL. A seropositive subject was a subjects with antibody concentration ≥ 2.693 IU/mL for anti-PT, ≥ 2.046 IU/mL for anti-FHA and ≥ 2.187 IU/mL for anti-PRN.
Time frame: One month post vaccination (Day 30) during pregnancy
Anti-D, Anti-T, Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were determined by ELISA, tabulated as GMCs and expressed in IU/mL.
Time frame: One month post vaccination (Day 30) during pregnancy
Percentage of Subjects With Vaccine Response to Anti-D and Anti-T
Vaccine response for anti-D and anti-T was defined as: for initially seronegative subjects (S-) with pre-vaccination concentration below cut-off: \< 0.1 IU/mL) was an antibody concentration at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL); for initially seropositive subjects (S+) with pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration.
Time frame: One month post vaccination (Day 30) during pregnancy
Percentage of Subjects With Vaccine Response to Anti-PT, Anti-FHA and Anti-PRN
Vaccine response to PT, FHA and PRN antigens is defined as: for subjects with pre-vaccination antibody concentration below the assay cut-off (S-), post-vaccination anti-body concentration ≥ 4 times the assay cut-off; for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off (S+), post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and for subjects with pre-vaccination antibody concentration ≥4 times the assay cut-off (S+), post-vaccination antibody concentration ≥2 times the pre-vaccination antibody concentration.
Time frame: One month post vaccination (Day 30) during pregnancy
Percentage of Seropositive Subjects Against Anti-PT, Anti-FHA and Anti-PRN in the Cord Blood Samples
For this assay the anti-PT, anti-FHA and anti-PRN seropositivity status was determined from the cord blood samples. The seropositivity cut-offs were the following: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.
Time frame: At delivery - Visit 3 (anytime after 27 eligible weeks of gestation)
Percentage of Subjects With Solicited Local Adverse Events (AEs)
Assessed solicited local symptoms were pain, redness and swelling. "Any" = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.
Time frame: During the 8-day (Day 0-Day 7) follow-up period after vaccination during pregnancy
Percentage of Subjects With Solicited General AEs
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache and fever \[defined as oral, axillary or tympanic temperature ≥ 37.5 degrees Celsius (°C) or rectal temperature ≥ 38.0 °C\]. "Any" = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.
Time frame: During the 8-day (Day 0-Day 7) follow-up period after vaccination during pregnancy
Percentage of Subjects With Unsolicited AEs
An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.
Time frame: Within 31 days (Day 0 - Day 30) after each vaccination
Percentage of Infants With Unsolicited AEs
An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
Time frame: From delivery to Month 2 post delivery (Visit 4, end of the study).
Number of Subjects With Serious AEs (SAEs)
A SAE was any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).
Percentage of Household Contacts of the Infants Born to Pregnant Women Vaccinated in Spain
This analysis assessed the vaccination status of the household contacts (who accepted, received or refused vaccination) and also the reasons for refusal (not coming to site, refused to be vaccinated, unspecified) as part of an assessment of cocooning among the eligible household contacts.
Time frame: From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study).
Percentage of Household Contacts With SAEs
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Time frame: During the 31-day (Days 0-30) follow-up period post-vaccination (Boostrix administered preferably 2 weeks before the birth of the infant, Visit 3).
A total of 725 pregnant subjects were screened of which 690 were randomized to 2 groups. Of these, 2 subjects were withdrawn before vaccination. Therefore 688 subjects were enrolled: 1 subject was excluded from the statistical analysis, leaving 687 subjects that comprised the Total Vaccinated cohort.
| Milestone | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Started | 341 | 346 |
| Completed | 325 | 335 |
| Not completed | 16 | 11 |
| Withdrew: Serious adverse event | 1 | 0 |
| Withdrew: Protocol violation | 3 | 2 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Lost to follow-up (partial vaccination) | 1 | 0 |
| Withdrew: Lost to follow-up (complete vaccination) | 6 | 5 |
| Withdrew: Other | 0 | 1 |
Antibody concentrations were assessed by Enzyme-linked immunosorbent assay (ELISA), tabulated as Geometric Mean Concentrations (GMCs) and expressed in International units per mililiter (IU/mL) for the following assay cut-offs: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.
| IU/mL | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Anti-PT | 46.9 (41.2 to 53.3) | 5.5 (4.8 to 6.3) |
| Anti-FHA | 366.1 (329 to 407.3) | 22.7 (19.7 to 26.2) |
| Anti-PRN | 301.8 (250.9 to 362.9) | 14.6 (12.1 to 17.7) |
Pregnancy outcomes included live birth with no congenital anomalies, live birth with congenital anomalies, still birth with no congenital anomalies, still birth with congenital anomalies, elective termination with no congenital anomalies and elective termination with congenital anomalies. No subjects with still birth or elective termination of infant were reported.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Live infant No apparent congenital anomaly | 97.4 (95 to 98.8) | 97.4 (95.1 to 98.8) |
| Live infant congenital anomaly | 2.6 (1.2 to 5) | 2.3 (1 to 4.5) |
| Lost to follow-up | 0 (0 to 1.1) | 0.3 (0 to 1.6) |
Listed pregnancy-related adverse events of interest/ neonate-related events of interest included gestational diabetes, pregnancy-related hypertension, premature rupture of mem-branes, preterm premature rupture of membranes, premature labour, premature uterine contractions, intrauterine growth restriction/poor foetal growth, pre-eclampsia, eclampsia, vaginal or intrauterine haemorrhage, maternal death, preterm birth, neonatal death, small for gestational age, neonatal hypoxic ischaemic encephalopathy and failure to thrive/growth deficiency were reported.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Intrauterine growth restriction/poor foetal growth | 1.5 (0.5 to 3.4) | 0.6 (0.1 to 2.1) |
| Pre-eclampsia | 0.3 (0 to 1.6) | 1.4 (0.5 to 3.3) |
| Pregnancy-related hypertension | 1.2 (0.3 to 3) | 1.4 (0.5 to 3.3) |
| Premature labour | 3.8 (2 to 6.4) | 3.2 (1.6 to 5.6) |
| Premature rupture of membranes | 3.8 (2 to 6.4) | 4.3 (2.4 to 7) |
| Premature uterine contractions | 0.6 (0.1 to 2.1) | 0.9 (0.2 to 2.5) |
| Preterm birth | 3.2 (1.6 to 5.7) | 2.6 (1.2 to 4.9) |
| Preterm premature rupture of membranes | 1.2 (0.3 to 3) | 2 (0.8 to 4.1) |
| Small for gestational age | 0.6 (0.1 to 2.1) | 0.6 (0.1 to 2.1) |
| Vaginal or intrauterine haemorrhage | 2.6 (1.2 to 5) | 2.9 (1.4 to 5.3) |
A seroprotected subject against diphteria and tetanus was a subject with antibody concentration ≥ 0.1 IU/mL. A seropositive subject was a subjects with antibody concentration ≥ 2.693 IU/mL for anti-PT, ≥ 2.046 IU/mL for anti-FHA and ≥ 2.187 IU/mL for anti-PRN.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Anti-D | 97.6 (95.1 to 99) | 70.6 (65 to 75.8) |
| Anti-T | 100 (98.7 to 100) | 96.6 (93.8 to 98.3) |
| Anti-PT | 98.6 (96.5 to 99.6) | 61.3 (55.5 to 66.9) |
| Anti-FHA | 100 (98.7 to 100) | 94.5 (91.2 to 96.8) |
| Anti-PRN | 100 (98.7 to 100) | 84.5 (79.9 to 88.5) |
Antibody concentrations were determined by ELISA, tabulated as GMCs and expressed in IU/mL.
| IU/mL | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Anti-D | 2.19 (1.87 to 2.57) | 0.23 (0.19 to 0.27) |
| Anti-T | 8.43 (7.72 to 9.2) | 0.98 (0.86 to 1.11) |
| Anti-PT | 45.6 (40.4 to 51.5) | 4.1 (3.6 to 4.6) |
| Anti-FHA | 317.5 (285 to 353.8) | 15 (13.1 to 17.2) |
| Anti-PRN | 283.6 (237.1 to 339.1) | 10.5 (8.7 to 12.5) |
Vaccine response for anti-D and anti-T was defined as: for initially seronegative subjects (S-) with pre-vaccination concentration below cut-off: \< 0.1 IU/mL) was an antibody concentration at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL); for initially seropositive subjects (S+) with pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Anti-D, S- | 64.1 (54 to 73.3) | 0 (0 to 4.3) |
| Anti-D, S+ | 75 (68.1 to 81.1) | 0 (0 to 1.8) |
| Anti-D, Total | 71.1 (65.5 to 76.3) | 0 (0 to 1.3) |
| Anti-T, S- | 100 (73.5 to 100) | 0 (0 to 30.8) |
| Anti-T, S+ | 67.8 (61.9 to 73.2) | 0 (0 to 1.3) |
| Anti-T, Total | 69.1 (63.4 to 74.4) | 0 (0 to 1.3) |
Vaccine response to PT, FHA and PRN antigens is defined as: for subjects with pre-vaccination antibody concentration below the assay cut-off (S-), post-vaccination anti-body concentration ≥ 4 times the assay cut-off; for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off (S+), post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and for subjects with pre-vaccination antibody concentration ≥4 times the assay cut-off (S+), post-vaccination antibody concentration ≥2 times the pre-vaccination antibody concentration.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Anti-PT, S- | 82.6 (74.7 to 88.9) | 0.9 (0 to 5.1) |
| Anti-PT, S+ (<4 cut-off) | 90.7 (83.6 to 95.5) | 0 (0 to 3.1) |
| Anti-PT, S+ (≥4 cut-off) | 93.1 (83.3 to 98.1) | 3 (0.4 to 10.4) |
| Anti-PT, Total | 87.8 (83.4 to 91.4) | 1 (0.2 to 3) |
| Anti-FHA, S- | 100 (79.4 to 100) | 0 (0 to 20.6) |
| Anti-FHA, S+ (<4 cut-off) | 100 (95.7 to 100) | 0 (0 to 5.5) |
| Anti-FHA, S+ (≥4 cut-off) | 89.9 (84.7 to 93.8) | 1.9 (0.5 to 4.8) |
| Anti-FHA, Total | 93.4 (89.9 to 96) | 1.4 (0.4 to 3.5) |
| Anti-PRN, S- | 86.7 (73.2 to 94.9) | 0 (0 to 8.2) |
| Anti-PRN, S+ (<4 cut-off) | 95.9 (89.9 to 98.9) | 0 (0 to 4.2) |
| Anti-PRN, S+ (≥4 cut-off) | 86.2 (79.5 to 91.4) | 1.2 (0.2 to 4.4) |
| Anti-PRN Total | 89.6 (85.5 to 92.9) | 0.7 (0.1 to 2.5) |
For this assay the anti-PT, anti-FHA and anti-PRN seropositivity status was determined from the cord blood samples. The seropositivity cut-offs were the following: 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Anti-PT | 98.6 (96.5 to 99.6) | 68.8 (63.2 to 74.1) |
| Anti-FHA | 100 (98.7 to 100) | 96.6 (93.8 to 98.3) |
| Anti-PRN | 99.7 (98.1 to 100) | 88 (83.7 to 91.5) |
Assessed solicited local symptoms were pain, redness and swelling. "Any" = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Any Pain, Dose 1 | 86.3 (82.1 to 89.8) | 14.6 (11 to 18.8) |
| Any Redness (mm), Dose 1 | 28.7 (23.9 to 33.8) | 12.8 (9.5 to 16.8) |
| Any Swelling (mm), Dose 1 | 25.1 (20.5 to 30.1) | 3.5 (1.8 to 6) |
| Any Pain, Dose 2 | 12.7 (9.2 to 16.8) | 62.7 (57.3 to 68) |
| Any Redness (mm), Dose 2 | 10.5 (7.4 to 14.4) | 29.7 (24.8 to 34.9) |
| Any Swelling (mm), Dose 2 | 5.2 (3.1 to 8.3) | 26.4 (21.7 to 31.5) |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), headache and fever \[defined as oral, axillary or tympanic temperature ≥ 37.5 degrees Celsius (°C) or rectal temperature ≥ 38.0 °C\]. "Any" = any report of the specified symptom irrespective of intensity grade. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Any Fatigue, Dose 1 | 43.6 (38.2 to 49.1) | 36.3 (31.2 to 41.6) |
| Any Gastrointestinal symptom, Dose 1 | 17.9 (14 to 22.4) | 15.2 (11.6 to 19.5) |
| Any Headache, Dose 1 | 24.8 (20.2 to 29.8) | 22.8 (18.5 to 27.6) |
| Any Temperature/(Axillary) (°C), Dose 1 | 1.2 (0.3 to 3) | 0.9 (0.2 to 2.5) |
| Any Fatigue, Dose 2 | 40.1 (34.7 to 45.7) | 46.2 (40.8 to 51.8) |
| Any Gastrointestinal symptom, Dose 2 | 9.9 (6.9 to 13.7) | 12.7 (9.3 to 16.8) |
| Any Headache, Dose 2 | 23.1 (18.7 to 28.1) | 23.6 (19.1 to 28.5) |
| Any Temperature/(Axillary) (°C), Dose 2 | 4.6 (2.6 to 7.5) | 9.1 (6.2 to 12.7) |
An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Dose 1 = pregnancy dose at Day 0 - Visit 1, Dose 2 = post-delivery dose at birth - Visit 3.
| Percentage of subjects | dTpa Group - Mother | Control Group - Mother |
|---|---|---|
| Any unsolicited AE, Dose 1 | 38.7 (33.5 to 44.1) | 35.5 (30.5 to 40.8) |
| Any unsolicited AE, Dose 2 | 30.7 (25.8 to 35.9) | 32.2 (27.2 to 37.4) |
An unsolicited AE was any AE that was not solicited using a subject diary and that was spontaneously communicated by the subject. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
| Percentage of subjects | dTpa Group - Infant | Control Group - Infnat |
|---|---|---|
| Percentage of Infants With Unsolicited AEs | 26.4 (21.8 to 31.4) | 22.3 (18.0 to 27.0) |
A SAE was any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | dTpa Group - Mother | Control Group - Mother | dTpa Group - Infant | Control Group - Infant | Household Group |
|---|---|---|---|---|---|
| Number of Subjects With Serious AEs (SAEs) | 51 | 52 | 52 | 45 | 0 |
This analysis assessed the vaccination status of the household contacts (who accepted, received or refused vaccination) and also the reasons for refusal (not coming to site, refused to be vaccinated, unspecified) as part of an assessment of cocooning among the eligible household contacts.
| Percentage of household contacts | Household Group |
|---|---|
| Accepted vaccination | 84.4 (81.5 to 86.9) |
| Received vaccination | 84.1 (81.2 to 86.7) |
| Refused vaccination | 15.6 (13.1 to 18.5) |
| Not coming to site | 1.4 (0.7 to 2.5) |
| Refused to be vaccinated | 13.4 (11 to 16.1) |
| Unspecified | 0.8 (0.3 to 1.8) |
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
| Percentage of subjects | Household Group |
|---|---|
| Percentage of Household Contacts With SAEs | 0 |
Collected over For the Mothers' Groups: Solicited local and general AEs were reported during Days 0 - 7 following each dose. Unsolicited AEs were reported during Days 0 - 30 following each dose. SAEs were reported during the entire study period (Day 0 up to Month 2). For the Infants' Groups: unsolicited AEs and SAEs were reported From Day 0 (Visit 1) to Month 2 (Visit 4, end of the study). For the Household Group: SAEs were reported during the 31-day (Days 0-30) follow-up period post-vaccination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| dTpa Group-Mother | 0/341 (0%) | 51/341 (15%) | 321/341 (94.1%) |
| Control Group-Mother | 0/346 (0%) | 52/346 (15%) | 303/346 (87.6%) |
| dTpa Group - Infant | 0/341 (0%) | 52/341 (15.2%) | 33/341 (9.7%) |
| Control Group-Infant | 0/346 (0%) | 45/346 (13%) | 29/346 (8.4%) |
| Household Group | 0/608 (0%) | 0/608 (0%) | 0/608 (0%) |
| Event | dTpa Group-Mother | Control Group-Mother | dTpa Group - Infant | Control Group-Infant | Household Group |
|---|---|---|---|---|---|
| Premature rupture of membranesPregnancy, puerperium and perinatal conditions | 13/341 | 17/346 | 0/341 | 0/346 | 0/608 |
| Premature babyPregnancy, puerperium and perinatal conditions | 0/341 | 0/346 | 11/341 | 9/346 | 0/608 |
| Premature labourPregnancy, puerperium and perinatal conditions | 11/341 | 11/346 | 0/341 | 0/346 | 0/608 |
| JaundiceHepatobiliary disorders | 0/341 | 0/346 | 8/341 | 6/346 | 0/608 |
| Postpartum haemorrhagePregnancy, puerperium and perinatal conditions | 5/341 | 7/346 | 0/341 | 0/346 | 0/608 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/341 | 0/346 | 5/341 | 4/346 | 0/608 |
| Pre-eclampsiaPregnancy, puerperium and perinatal conditions | 1/341 | 5/346 | 0/341 | 0/346 | 0/608 |
| Preterm premature rupture of membranesPregnancy, puerperium and perinatal conditions | 4/341 | 5/346 | 0/341 | 0/346 | 0/608 |
| Gestational hypertensionPregnancy, puerperium and perinatal conditions | 4/341 | 4/346 | 0/341 | 0/346 | 0/608 |
| Premature deliveryPregnancy, puerperium and perinatal conditions | 4/341 | 4/346 | 0/341 | 0/346 | 0/608 |
| Event | dTpa Group-Mother | Control Group-Mother | dTpa Group - Infant | Control Group-Infant | Household Group |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 290/341 | 223/346 | 0/341 | 0/346 | 0/608 |
| FatigueGeneral disorders | 188/341 | 186/346 | 0/341 | 0/346 | 0/608 |
| HeadacheNervous system disorders | 129/341 | 126/346 | 0/341 | 0/346 | 0/608 |
| Injection site erythemaGeneral disorders | 106/341 | 117/346 | 0/341 | 0/346 | 0/608 |
| Injection site swellingGeneral disorders | 91/341 | 92/346 | 0/341 | 0/346 | 0/608 |
| Gastrointestinal disorderGastrointestinal disorders | 78/341 | 83/346 | 0/341 | 0/346 | 0/608 |
| PyrexiaGeneral disorders | 20/341 | 32/346 | 0/341 | 0/346 | 0/608 |
| Afterbirth painPregnancy, puerperium and perinatal conditions | 17/341 | 20/346 | 0/341 | 0/346 | 0/608 |
| AnaemiaBlood and lymphatic system disorders | 11/341 | 14/346 | 0/341 | 0/346 | 0/608 |
| MastitisInfections and infestations | 10/341 | 14/346 | 0/341 | 0/346 | 0/608 |
| Age, Continuous(Years) | dTpa Group - Mother | Control Group - Mother | Total |
|---|---|---|---|
| Mean | 32.7 ± 4.4 | 32.5 ± 4.3 | 32.6 ± 4.35 |
| Sex/Gender, Customized(Participants) | dTpa Group - Mother | Control Group - Mother | Total |
|---|---|---|---|
| Female | 341 | 346 | 687 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | dTpa Group - Mother | Control Group - Mother | Total |
|---|---|---|---|
| African Heritage / African American | 3 | 9 | 12 |
| American Indian or Alaskan Native | 2 | 0 | 2 |
| Asian - Central/South Asian Heritage | 3 | 0 | 3 |
| Asian - East Asian Heritage | 4 | 1 | 5 |
| Asian - Japanese Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 1 | 1 | 2 |
| White - Arabic / North African Heritage | 3 | 7 | 10 |
| White - Caucasian / European Heritage | 314 | 319 | 633 |
| Unspecified | 10 | 9 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2015 to primary completion in Aug 2017, 22 months.
Results were first posted in Jan 2019, 1 year 5 months after primary completion.
Of 21 phase 4 interventional studies under Diphtheria, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's 22 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix